The COVID-19 pandemic
The evolving COVID-19 pandemic is profoundly impacting our lives, and places tremendous strain on healthcare systems and society at large. Since the start of the crisis, UCB has taken measures to protect our colleagues around the world, to stand by patients, to help our communities and take our part in the global response to the pandemic. We know that it is our responsibility to help where we can make an impact.
A word from Jean-Christophe Tellier, CEO of UCB
The world today is facing an unprecedented challenge as it fights against the COVID-19 pandemic. UCB is helping there where it can make a real impact for patients, people, and society. Read more
UCB's statement on the impact of the COVID-19 outbreak
Official statement on the impact of COVID-19 outbreak on our employees, supply of medicines, clinical studies and our suppliers. Find out more
COVID-19 questions?
If you are a patient or a healthcare professional and have questions or need support
in the context of COVID-19, please reach out to UCB Cares, contact details can be
found here
UCB Community Health Fund
UCB has set up a Gobal Fund to support vulnerable people facing economic and health disadvantage across communities in which the company operates. The initial focus will be on contributing to understand and reduce the medium- and long-term impacts of the COVID-19 pandemic on vulnerable populations’ physical, mental, and social well-being. Learn more
Our part in the global response
These are challenging times. The surge of cases of COVID-19 is having a profound impact on people around the world, putting pressure on our health systems and disrupting all our daily lives. It is heartening to seeing the wave of solidarity coming from companies, organizations and individuals. At UCB we are also looking to do our part. Read more
COVID R&D Alliance
UCB is a member of the COVID R&D Alliance that brings together the world’s most experienced and
accomplished leaders in therapeutic drug research and development, all working together to identify
and accelerate promising therapeutic candidates for COVID-19 and its related symptoms.
